Nyxoah SA (NYXH)

NASDAQ: NYXH · IEX Real-Time Price · USD
4.98
-0.22 (-4.23%)
Dec 2, 2022 4:00 PM EST - Market closed
-4.23%
Market Cap 140.40M
Revenue (ttm) 2.07M
Net Income (ttm) -24.18M
Shares Out 25.77M
EPS (ttm) -1.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,038
Open 5.08
Previous Close 5.2
Day's Range 4.91 - 5.24
52-Week Range 4.91 - 23.05
Beta 0.87
Analysts Buy
Price Target 24.89 (+399.8%)
Earnings Date Nov 8, 2022

About NYXH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. [Read more]

Industry Medical Instruments & Supplies
IPO Date Jul 2, 2021
CEO Olivier Taelman
Employees 105
Stock Exchange NASDAQ
Ticker Symbol NYXH
Full Company Profile

Financial Performance

In 2021, Nyxoah's revenue was 852,000, an increase of 1,134.78% compared to the previous year's 69,000. Losses were -27.62 million, 125.6% more than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for NYXH stock is "Buy." The 12-month stock price forecast is 24.89, which is an increase of 399.80% from the latest price.

Price Target
$24.89
(399.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nyxoah to Participate in the Piper Sandler 34 th Annual Healthcare Conference

2 weeks ago - GlobeNewsWire

Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?

The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 240% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

2 weeks ago - Zacks Investment Research

Nyxoah Announces Change to Board of Directors

Nyxoah A nnounces C hange to Board of Directors

1 month ago - GlobeNewsWire

Nyxoah to Participate in the Jefferies London Healthcare Conference

Nyxoah to Participate in the Jefferies London Healthcare Conference

1 month ago - GlobeNewsWire

Nyxoah to Release Third Quarter Financial Results on November 8, 2022

Nyxoah to Release Third Quarter Financial Results on November 8 , 2022

1 month ago - GlobeNewsWire

Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference

Mont-Saint-Guibert, Belgium – August 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development an...

3 months ago - GlobeNewsWire

Wall Street Analysts Believe Nyxoah SA (NYXH) Could Rally 170%: Here's is How to Trade

The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 170.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

3 months ago - Zacks Investment Research

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test

Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test

4 months ago - GlobeNewsWire

Nyxoah to Present at the Canaccord Genuity 42nd Annual Growth Conference

Mont-Saint-Guibert, Belgium – July 27, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and ...

4 months ago - GlobeNewsWire

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022

Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022

4 months ago - GlobeNewsWire

Nyxoah Announces CE Mark Approval for Genio® 2.1

The next generation external activation chip leverages Nyxoah's scalable platform to continuously enhance patient comfort and therapy efficacy

4 months ago - GlobeNewsWire

Nyxoah SA (NYXH) Stock Jumps 13.2%: Will It Continue to Soar?

Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

4 months ago - Zacks Investment Research

FDA Signs Off Nyxoah's Genio Trial In Complete Concentric Collapse Patients

The FDA has approved Nyxoah SA's (NASDAQ: NYXH) Investigational Device Exemption (IDE) to initiate a trial, called ACCCESS, to evaluate the Genio system for moderate-to-severe Obstructive Sleep Apnea (O...

4 months ago - Benzinga

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index

5 months ago - GlobeNewsWire

FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study

FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study

6 months ago - GlobeNewsWire

Nyxoah Reports First Quarter 2022 Financial and Operating Results

REGULATED INFORMATION

6 months ago - GlobeNewsWire

Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors

Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors

6 months ago - GlobeNewsWire

Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 8, 2022

REGULATED INFORMATION May 6, 2022, 7:00am CET / 1:00am ET

6 months ago - GlobeNewsWire

Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022

Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022

7 months ago - GlobeNewsWire

Nyxoah Reports Full Year 2021 Operating and Financial Results

REGULATED INFORMATION

8 months ago - GlobeNewsWire

Should You Buy Nyxoah (NYXH) Ahead of Earnings?

Nyxoah (NYXH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

8 months ago - GlobeNewsWire

Nyxoah to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Nyxoah to Participate in the Oppenheimer 32nd Annual Healthcare Conference

8 months ago - GlobeNewsWire